Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tigilanol tiglate
- Development stage
- Phase 2
- Lead developer
- Qbiotics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intratumoral
01
Overview
Tigilanol tiglate is a naturally occurring small molecule diterpenoid, specifically a phorbol ester, isolated from the seeds of the Australian blushwood tree (Fontainea picrosperma)[4][5]. It is approved as a veterinary pharmaceutical for the intratumoral treatment of non-metastatic and non-resectable canine mast cell tumors[1][2][3][4]. The drug acts primarily by activating protein kinase C (PKC) isoforms, which disrupts tumor vasculature and induces an acute inflammatory response at the injection site. This leads to rapid hemorrhagic necrosis and destruction of tumor cells through oncosis, followed by immune cell recruitment and wound healing[1][6][8]. Tigilanol tiglate has also received orphan drug designation from the FDA for soft tissue sarcoma in humans and is under clinical investigation for various solid tumors in both human and veterinary medicine[5][6][7].
- Brand names
- Stelfonta
- Other names
- tigilanol tiglate
02
Targets
PKC (Protein kinase C family)
Beyond the preview
Go deeper on tigilanol tiglate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tigilanol tiglate.